Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Observational Study to Evaluate the Clinical Impact of BTK Inhibitor-Based Regimens in Treatment-Naïve Patients With Mantle Cell Lymphoma (MCL) in Italian Clinical Practice.

9. november 2026 oppdatert av: Fondazione Italiana Linfomi - ETS

An Observational Cohort Study to Evaluate the Clinical Impact of BTK Inhibitor-Based Regimens in Treatment-Naïve Patients With Mantle Cell Lymphoma (MCL) in Italian Clinical Practice.

Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin lymphoma (B-NHL), characterized by a heterogeneous clinical course and, in a substantial proportion of patients, an aggressive disease behavior requiring timely and effective treatment at diagnosis.

In recent years, the therapeutic landscape of MCL has undergone a major transformation with the introduction of Bruton's tyrosine kinase inhibitors (BTKis). Ibrutinib, acalabrutinib, zanubrutinib, and the non-covalent BTKi pirtobrutinib have demonstrated substantial clinical activity in relapsed/refractry (R/R) MCL. Their role has progressively expanded beyond the relapsed/refractory setting, with BTK inhibitor-based regimens increasingly being incorporated into frontline treatment strategies, supported by emerging clinical trial evidence and reflected in evolving treatment guidelines and clinical practice.

Despite this rapidly evolving treatment landscape, real-world evidence on the use of BTKi-based regimens in the frontline setting remains limited. In particular, data on treatment selection, efficacy, safety, treatment duration, and management of toxicities in routine clinical practice are still scarce.

We therefore propose an observational cohort study to evaluate the clinical impact of previously untreated patients with MCL receiving frontline BTKi-based regimens in routine clinical practice in Italy. The study will assess treatment patterns, effectiveness, safety, and treatment persistence, providing real-world insights into the use of these strategies beyond clinical trials.

Studieoversikt

Status

Har ikke rekruttert ennå

Studietype

Observasjonsmessig

Registrering (Antatt)

500

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Previously untreated patients with Mantle Cell Lymphoma receiving frontline Bruton's Tyrosin Kinase-based treatment in routine clinical practice in Italy.

Beskrivelse

Inclusion criteria:

General Inclusion Criteria:

  • Histologically confirmed diagnosis of mantle cell lymphoma (MCL) requiring treatment according to current clinical guidelines and standard-of-care recommendations.
  • Age ≥ 18 years at the time of BTKi-based treatment initiation.
  • Patients who are able to understand the nature and objectives of the study and who have provided written informed consent, approved by the Independent Ethics Committee (IEC), for participation in the observational study.

For the retrospective enrollment group:

In addition to the general inclusion criteria, patients included in the retrospective cohort must meet the following criterion:

● Patients eligible for BTKi-based treatment before the relevant marketing authorization (AIC) in Italy, includingthose treated through off-label use, compassionate use programs, or under Italian Law 648/96, as applicable.

For the prospective enrollment group:

In addition to the general inclusion criteria, patients included in the prospective cohort must meet the following criterion:

● Patients eligible for a BTKi-based regimen in accordance with the EMA-approved indication and the corresponding AIC in Italy.

Exclusion criteria:

  • Diagnosis of a histological subtype of lymphoma other than mantle cell lymphoma (MCL).
  • Concurrent participation in a prospective interventional clinical trial that may interfere with the assessment of treatment exposure, efficacy, safety, or other study endpoints.
  • Inability or unwillingness to provide written informed consent, where required by applicable ethical and regulatory requirements.
  • Any condition that, in the investigator's judgment, may preclude reliable collection or interpretation of study data or compromise the patient's ability to participate in the study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: CROSS_SECTIONAL

Kohorter og intervensjoner

Gruppe / Kohort
Retrospective enrollment group

Patients who had an indication for a BTKi-based regimen before the marketing authorization (AIC) in Italy. This group may include patients treated before the relevant AIC through off-label use, compassionate use programs, or treatment provided under Italian Law 648/96.

Prospective enrollment group

Patients eligible for a BTKi-based regimen in accordance with the EMA approved indication and the corresponding AIC in Italy.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Best overall response
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined according to Lugano 2014 criteria as the best response recorded between the start of therapy and the end of treatment. Overall response rate (ORR) includes complete (CR) and partial response (PR). Patients without response assessment for any reason are considered non-responders.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Progression-free survival (PFS)
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to the first documentation of relapse, progression or death from any cause. Patients alive without progression are censored at the date of last disease assessment.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Overall survival (OS)
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to death from any cause. Patients alive are censored at the date of last contact.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Event-free survival (EFS)
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to progression, death from any cause or initiation of a new anti-lymphoma treatment (NALT) without documented progression.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Time to next treatment (TTNT)
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to the initiation of a NALT.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Duration of response (DOR)
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined in responding patients as the time from the first documentation of CR or PR to progression or death from any cause

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Non-relapse mortality (NRM)
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as death without prior relapse or progression

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
POD24
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as relapse or progression within 24 months from diagnosis (early POD) or later than 24 months (late POD)

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Incidence of adverse events
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Incidence of grade 3, 4 and 5 adverse events according to the latest NCI CTCAE version, and of serious adverse events, occurring after the first dose or at any time during therapy.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Incidence of deaths
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Deaths occurring during treatment, at the end of treatment, and during follow-up, with specific assessment of early deaths (defined as deaths occurring within 3 months from treatment initiation), treatment-related (toxic) deaths, and causes of death (any).

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Treatment duration
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to permanent discontinuation for any reason.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Treatment discontinuation
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Incidence and reasons for treatment discontinuation (progression, toxicity, death, patient preference, physician decision, planned completion, other).

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Treatment modifications
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Frequency and reasons for dose reductions, interruptions and other modifications.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Marco Ladetto, MD, S.C.D.U. Ematologia, I.R.C.C.S. A.O.U. SS. Antonio e Biagio e Cesare Arrigo - Alessandria

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. mars 2027

Primær fullføring (Antatt)

1. mars 2042

Studiet fullført (Antatt)

1. mars 2042

Datoer for studieregistrering

Først innsendt

9. november 2026

Først innsendt som oppfylte QC-kriteriene

9. november 2026

Først lagt ut (Faktiske)

16. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere